Efficiency of anti-VEGF ranibizumab in the treatment of retinopathy of prematurity

    Abstract

    Efficiency of anti-VEGF ranibizumab in the treatment of retinopathy of prematurity

    E.E. Sidorenko , A.O. Nazarenko , E.I. Sidorenko , S.A. Obrubov

    The N.I. Pirogov Russian National Research Medical University, Moscow
The V. F. Voino-Yasenetsky Scientific Practical Center of Specialized Medical Care for Children of the Health Department of Moscow City, Moscow

    Purpose. To study an efficacy of anti-VEGF ranibizumab medicine in the treatment of retinopathy of prematurity.

    Material and methods. The study included for a treatment 17 children with retinopathy of prematurity in the stage 3, 4, 5 «plus disease», «posterior aggressive». The results of the treatment in 10 patients were analyzed. The patients were examined using the retinal pediatric camera RetCam Shuttle (USA), the hand slit lamp Kowa SL-15 (Japan), ultrasonic investigations were carried out using the B-scan plus Accutome (USA), ophthalmoscopy with the direct ophthalmoscope Heine Beta 200S (Germany) and the binocular ophthalmoscope Heine Omega 500 (Germany). Ranibizumab was injected intravitreous using a dose of 0.125 mg monocularly in the operating room.

    Results and conclusions. Intravitreal injections of ranibizumab causes a decrease in exudation and the length of exudative retinal detachment, reduces vascular activity and the quantity of hemorrhages that allows to perform the vitreoretinal stage of surgical treatment at an earlier period.

    Key words: inhibitors of vascular endothelial growth factor, ranibizumab, retinopathy of prematurity.